Outlook Therapeutics (OTLK) Short Interest Ratio & Short Volume → What is Nvidia doing on June 10? June 10th is pivotal for Nvidia’s “Silent Partners” (From Weiss Ratings) (Ad) Free OTLK Stock Alerts $7.07 -0.15 (-2.08%) (As of 05/31/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Outlook Therapeutics Short Interest DataCurrent Short Interest1,330,000 sharesPrevious Short Interest1,260,000 sharesChange Vs. Previous Month+5.56%Dollar Volume Sold Short$9.88 millionShort Interest Ratio2.0 Days to CoverLast Record DateMay 15, 2024Outstanding Shares23,410,000 sharesFloat Size16,540,000 sharesShort Percent of Float8.04%Today's Trading Volume166,606 sharesAverage Trading Volume275,949 sharesToday's Volume Vs. Average60% Short Selling Outlook Therapeutics ? Sign up to receive the latest short interest report for Outlook Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartOTLK Short Interest Over TimeOTLK Days to Cover Over TimeOTLK Percentage of Float Shorted Over Time Ad The Freeport SocietyBiden Nomination CANCELED?The Hill just published that Joe Biden has received enough delegates to…“clinch the Democratic presidential nomination and all but guaranteeing he will face off against former President Trump again in November.” Why is he all BUT guaranteed the Democratic nomination, in their words?I believe I have the terrifying answer right here. Outlook Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/15/20241,330,000 shares $9.88 million +5.6%8.0%2 $7.43 4/30/20241,260,000 shares $11.24 million +11.5%7.7%2 $8.92 4/15/20241,130,000 shares $9.74 million -15.0%7.4%1.8 $8.62 3/31/20241,330,000 shares $15.88 million +69.4%6.2%2.2 $11.94 3/15/2024785,300 shares $6.47 million -93.3%10.6%1.6 $8.24 2/29/202411,640,000 shares $5.08 million -11.8%7.9%6 $0.44 Get the Latest News and Ratings for OTLK and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Outlook Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/15/202413,200,000 shares $6.40 million -2.7%9.0%6.5 $0.48 1/31/202413,570,000 shares $5.24 million +11.9%9.2%5.9 $0.39 1/15/202412,130,000 shares $4.47 million +7.3%9.2%1.9 $0.37 12/31/202311,310,000 shares $4.46 million +3.3%8.6%1.6 $0.39 12/15/202310,950,000 shares $4.20 million -32.1%8.3%1.5 $0.38 11/30/202316,130,000 shares $7.74 million -21.5%12.2%2.1 $0.48 11/15/202320,540,000 shares $9.16 million -35.9%16.0%1.8 $0.45 10/31/202332,030,000 shares $19.22 million +9.4%25.0%2.8 $0.60 10/15/202329,270,000 shares $9.51 million +9.5%22.9%3.2 $0.33 9/30/202326,720,000 shares $5.91 million +3.4%20.9%4.5 $0.22 9/15/202325,850,000 shares $5.56 million -3.0%20.2%4.6 $0.22 8/31/202326,660,000 shares $6.08 million +52.3%21.1%5.2 $0.23 8/15/202317,510,000 shares $27.14 million +4.9%13.9%12.2 $1.55 7/31/202316,700,000 shares $28.89 million +1.8%13.4%13.1 $1.73 7/15/202316,410,000 shares $27.08 million -2.2%13.2%13.2 $1.65 6/30/202316,770,000 shares $29.18 million -1.9%13.5%15.2 $1.74 6/15/202317,100,000 shares $30.44 million +3.9%13.7%16.6 $1.78 5/31/202316,460,000 shares $24.69 million +0.6%13.2%19.1 $1.50 5/15/202316,370,000 shares $19.64 million -3.1%13.1%24.5 $1.20 4/30/202316,890,000 shares $17.73 million +0.6%13.6%28.6 $1.05 4/15/202316,790,000 shares $18.13 million +2.2%13.6%29.7 $1.08 3/31/202316,430,000 shares $17.91 million +6.1%13.3%27.6 $1.09 3/15/202315,490,000 shares $15.64 million +2.9%12.5%24.9 $1.01 2/28/202315,050,000 shares $16.40 million -1.4%12.2%27.1 $1.09 2/15/202315,270,000 shares $17.71 million -2.9%12.4%29 $1.16 1/31/202315,730,000 shares $18.09 million +3.8%11.7%32 $1.15 1/15/202315,150,000 shares $20.45 million -5.4%12.7%30.2 $1.35 12/30/202216,020,000 shares $17.30 million +0.4%33.0%36.9 $1.08 12/15/202215,960,000 shares $14.37 million -1.1%12.1%34.6 $0.90 11/30/202216,130,000 shares $16.78 million -1.7%12.2%35.1 $1.04 11/15/202216,400,000 shares $17.38 million +3.0%12.4%34.7 $1.06 10/31/202215,930,000 shares $18.48 million +3.6%12.0%33.8 $1.16 10/15/202215,380,000 shares $18.46 million +6.7%11.6%33.4 $1.20 9/30/202214,420,000 shares $17.59 million +5.6%10.9%30.8 $1.22Who are Nvidia’s New Silent Partners? (Ad)Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.I call these Nvidia’s “Silent Partners.” 9/15/202213,660,000 shares $15.71 million +9.2%10.3%29.1 $1.15 8/31/202212,510,000 shares $14.01 million +2.6%9.4%26.3 $1.12 8/15/202212,190,000 shares $15.36 million -0.7%9.2%13.9 $1.26 7/31/202212,280,000 shares $13.88 million +4.0%9.3%12.9 $1.13 7/15/202211,810,000 shares $13.82 million +5.7%8.9%12.2 $1.17 6/30/202211,170,000 shares $11.39 million +4.7%8.4%11 $1.02 6/15/202210,670,000 shares $10.59 million -8.3%6.5%9 $0.99 5/31/202211,640,000 shares $13.39 million +4.2%7.1%8.3 $1.15 5/15/202211,170,000 shares $17.87 million +4.6%6.8%9.3 $1.60 4/30/202210,680,000 shares $16.55 million +1.0%6.5%8.7 $1.55 4/15/202210,580,000 shares $19.26 million +9.3%9.9%7.6 $1.82 3/31/20229,680,000 shares $17.23 million +48.9%N/A6.5 $1.78 3/15/20226,500,000 shares $11.51 million +8.5%N/A4.6 $1.77 2/28/20225,990,000 shares $9.76 million +9.3%4.9%4.5 $1.63 2/15/20225,480,000 shares $7.67 million +3.4%4.5%3.4 $1.40 1/31/20225,300,000 shares $7.53 million +25.0%4.4%3.2 $1.42 1/15/20224,240,000 shares $5.64 million -1.9%3.5%2.8 $1.33 12/31/20214,320,000 shares $5.88 million +0.9%3.5%3.2 $1.36 12/15/20214,280,000 shares $6.21 million +16.3%3.5%3.2 $1.45 11/30/20213,680,000 shares $5.56 million -41.6%4.0%2.8 $1.51 11/15/20216,300,000 shares $12.29 million -1.4%7.1%5.7 $1.95 10/29/20216,390,000 shares $13.23 million +8.7%7.2%7.1 $2.07 10/15/20215,880,000 shares $12.41 million -3.5%6.7%2 $2.11 9/30/20216,090,000 shares $13.22 million +8.2%6.9%2.1 $2.17 9/15/20215,630,000 shares $13.62 million -0.5%6.4%1.8 $2.42 8/31/20215,660,000 shares $15.62 million +1.4%6.4%1.8 $2.76 8/13/20215,580,000 shares $13.39 million +71.7%6.3%1.8 $2.40 7/30/20213,250,000 shares $7.35 million +3.2%3.7%1.1 $2.26 7/15/20213,150,000 shares $7.15 million -25.2%3.6%3.4 $2.27 6/30/20214,210,000 shares $10.48 million +214.2%4.8%4.2 $2.49 6/15/20211,340,000 shares $3.46 million +6.4%1.5%1.5 $2.58 5/28/20211,260,000 shares $3.38 million +15.6%1.4%1.3 $2.68 5/14/20211,090,000 shares $2.11 million +41.8%N/A1 $1.94 4/30/2021768,600 shares $1.79 million +155.3%N/A0.3 $2.33 4/15/2021301,100 shares $563,057.00 -34.1%N/A0.1 $1.87 3/31/2021457,100 shares $996,478.00 +30.8%N/A0.1 $2.18 3/15/2021349,500 shares $782,880.00 +20.8%N/A0.1 $2.24 2/26/2021289,400 shares $616,422.00 -67.3%N/A0.1 $2.13 2/12/2021884,100 shares $2.29 million -55.1%N/A0.2 $2.59 1/29/20211,970,000 shares $2.40 million +25.5%N/A0.5 $1.22 1/15/20211,570,000 shares $1.93 million -19.9%N/A1.8 $1.23 12/31/20201,960,000 shares $2.61 million -2.5%N/A2.1 $1.33 12/15/20202,010,000 shares $2.65 million -3.4%N/A2.3 $1.32 11/30/20202,080,000 shares $2.56 million -25.2%N/A2.3 $1.23 11/15/20202,780,000 shares $2.89 million -13.9%N/A1.7 $1.04 10/30/20203,230,000 shares $2.60 million +4.5%N/A1.7 $0.81 10/15/20203,090,000 shares $2.70 million +8.8%N/A1.4 $0.87 9/30/20202,840,000 shares $2.04 million +16.9%N/A1.1 $0.72 9/15/20202,430,000 shares $1.56 million -9.3%N/A0.8 $0.64 8/31/20202,680,000 shares $1.77 million +0.4%N/A0.7 $0.66Who are Nvidia’s New Silent Partners? (Ad)Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.I call these Nvidia’s “Silent Partners.” 8/14/20202,670,000 shares $3.74 million +29.6%N/A0.8 $1.40 7/31/20202,060,000 shares $2.80 million -11.6%N/A0.7 $1.36 7/15/20202,330,000 shares $3.22 million +8.9%N/A0.8 $1.38 6/30/20202,140,000 shares $2.76 million -23.3%8.2%0.9 $1.29 6/15/20202,790,000 shares $3.12 million +29.8%14.3%1.6 $1.12 5/29/20202,150,000 shares $2.19 million +1.4%N/A2.1 $1.02 5/15/20202,120,000 shares $1.52 million -1.4%N/A2.8 $0.72 4/30/20202,150,000 shares $1.48 million -0.9%N/A4.1 $0.69 4/15/20202,170,000 shares $1.54 million -1.8%N/A4.1 $0.71 3/31/20202,210,000 shares $1.48 million +5.4%N/A4 $0.67 3/13/20202,097,400 shares $1.30 million +1.8%N/A5.6 $0.62 2/28/20202,060,000 shares $1.13 million -5.1%N/A2.2 $0.55 2/14/20202,170,000 shares $1.52 million +5.9%18.0%2 $0.70 1/31/20202,050,000 shares $1.60 million -21.2%17.0%2 $0.78 1/15/20202,600,000 shares $2.68 million +30.0%21.4%2.7 $1.03 12/31/20192,000,000 shares $2.08 million +13.6%18.3%2.3 $1.04 8/15/20191,363,300 shares $1.94 million +17.5%56.6%0.3 $1.42 OTLK Short Interest - Frequently Asked Questions What is Outlook Therapeutics' current short interest? Short interest is the volume of Outlook Therapeutics shares that have been sold short but have not yet been closed out or covered. As of May 15th, traders have sold 1,330,000 shares of OTLK short. 8.04% of Outlook Therapeutics' shares are currently sold short. Learn More on Outlook Therapeutics' current short interest. What is a good short interest ratio for Outlook Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. OTLK shares currently have a short interest ratio of 2.0. Learn More on Outlook Therapeutics's short interest ratio. What is a good short interest percentage for Outlook Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 8.04% of Outlook Therapeutics' floating shares are currently sold short. Is Outlook Therapeutics' short interest increasing or decreasing? Outlook Therapeutics saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 1,330,000 shares, an increase of 5.6% from the previous total of 1,260,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Outlook Therapeutics' float size? Outlook Therapeutics currently has issued a total of 23,410,000 shares. Some of Outlook Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Outlook Therapeutics currently has a public float of 16,540,000 shares. How does Outlook Therapeutics' short interest compare to its competitors? 8.04% of Outlook Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "biological products, except diagnostic" compare to Outlook Therapeutics: Coherus BioSciences, Inc. (18.98%), Champions Oncology, Inc. (0.92%), Protara Therapeutics, Inc. (6.61%), Brainstorm Cell Therapeutics Inc. (2.01%), REGENXBIO Inc. (8.14%), CARGO Therapeutics, Inc. (13.82%), HilleVax, Inc. (2.98%), iTeos Therapeutics, Inc. (7.82%), Taysha Gene Therapies, Inc. (9.11%), Valneva SE (0.10%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.81 billion), Charter Communications, Inc. ($3.30 billion), Occidental Petroleum Co. ($3.10 billion), General Motors ($2.84 billion), Moderna, Inc. ($2.77 billion), AppLovin Co. ($2.22 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.16 billion), Tractor Supply ($2.12 billion), and Williams-Sonoma, Inc. ($2.12 billion). View all of the most shorted stocks. What does it mean to sell short Outlook Therapeutics stock? Short selling OTLK is an investing strategy that aims to generate trading profit from Outlook Therapeutics as its price is falling. OTLK shares are trading down $0.15 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Outlook Therapeutics? A short squeeze for Outlook Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of OTLK, which in turn drives the price of the stock up even further. How often is Outlook Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including OTLK, twice per month. The most recent reporting period available is May, 15 2024. More Short Interest Resources from MarketBeat Related Companies: Coherus BioSciences Short Interest Data Champions Oncology Short Interest Data Protara Therapeutics Short Interest Data Brainstorm Cell Therapeutics Short Interest Data REGENXBIO Short Interest Data CARGO Therapeutics Short Interest Data HilleVax Short Interest Data iTeos Therapeutics Short Interest Data Taysha Gene Therapies Short Interest Data Valneva Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:OTLK) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersBiden Nomination CANCELED?The Freeport SocietyWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Outlook Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.